journal article·2026-07-07Open access

Modulation of Lung Adenocarcinoma by Phosphorylated FOXN3‐Mediated Transcriptional Inactivation of p53

Jinjin Yu, Jingyu Yu, Suhui Wang, Xinghong Hu, Lele Jin, Nan Wu, Yuhan Ni, Xueying Zhang, Chengling Zhao, Jihong Zhou, Yong Zhang, Baofa Sun, Hongxing Zhang, Chunfu Zheng, Song Guo Zheng, Wei Li, Xinxing Zhu

Abstract

ABSTRACT As a pivotal tumor suppressor, p53 plays a critical role in the progression of lung adenocarcinoma (LUAD). However, the mechanisms through which its interacting partners modulate p53 transcriptional activity remain poorly understood. In this study, we identified the transcription factor FOXN3 as a key partner that recruits p53 for transcriptional responses. FOXN3 directly interacts with p53, and the two factors exhibit extensive genome‐wide colocalization in both lung cancer cells and clinical tumor tissues, thereby co‐regulating the transcription of numerous genes. Notably, nearly all p53 point mutants with disrupted DNA‐binding capacity show markedly reduced association with FOXN3, underscoring the essential role of FOXN3 in facilitating p53 binding to DNA. Conditional knockout of FOXN3 promotes lung cancer cell survival, invasion, and tumorigenesis. Importantly, the regulation of p53 transcriptional activity by FOXN3 requires phosphorylation at the S83 and S85 sites. This phosphorylation induces the dissociation of FOXN3 from chromatin, thereby inhibiting p53 transcriptional recruitment and activation. Ablation of FOXN3 S83 and S85 phosphorylation impedes the progression of LUAD. Furthermore, increased phosphorylation of FOXN3 at S83 and S85 is observed in clinical lung tumor tissues and correlates with poor prognosis in patients with LUAD, highlighting its potential as a therapeutic target.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: FOXO transcription factor regulation · Telomeres, Telomerase, and Senescence · Cancer Cells and Metastasis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Anhui Province Key Laboratory of Respiratory Tumor and Infectious Disease Department of Respiratory and Critical Care Medicine First Affiliated Hospital Bengbu Medical University Bengbu China

Molecular Diagnosis Center Bengbu Medical University Bengbu China

Research Center of Clinical Laboratory Science School of Laboratory Medicine Bengbu Medical University Bengbu China

State Key Laboratory of Medicinal Chemical Biology Frontiers Science Center For Cell Responses College of Life Sciences Nankai University Tianjin China

School of Psychology Xinxiang Medical University Xinxiang China

Department of Microbiology Immunology & Infection Diseases University of Calgary Calgary Alberta Canada

Department of Immunology the School of Cell and Gene Therapy Songjiang Research Institute and Songjiang Hospital Affiliated to Shanghai Jiao Tong Uniersity School of Medicine Shanghai China

Innovative Medical Research Institute Bengbu Medical University Bengbu China

Center For Clinical Medicine of Respiratory Disease (tumor) in Anhui Bengbu China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Anhui Province

References (56)

Show source-provided references
1. 10.1016/j.molmed.2019.04.01210.1016/j.molmed.2019.04.012 ↗
2. 10.21037/tlcr.2016.06.0710.21037/tlcr.2016.06.07 ↗
3. p53 Signaling on Microenvironment and its Contribution to Tissue Chemoresistance10.3390/membranes12020202 ↗
4. 10.1146/annurev‐pathol‐042320‐02584010.1146/annurev‐pathol‐042320‐025840 ↗
5. 10.1038/cdd.2017.16910.1038/cdd.2017.169 ↗
6. 10.1016/j.ccell.2021.01.00310.1016/j.ccell.2021.01.003 ↗
7. 10.1016/j.phrs.2018.03.01510.1016/j.phrs.2018.03.015 ↗
8. 10.1038/s41418‐022‐00943‐y10.1038/s41418‐022‐00943‐y ↗
9. and Myofibroblast Apoptosis in Organ Fibrosis10.3390/ijms24076737 ↗
10. 10.1038/nrc258410.1038/nrc2584 ↗
11. 10.1080/15548627.2021.200875210.1080/15548627.2021.2008752 ↗
12. 10.1016/j.tcb.2020.12.01110.1016/j.tcb.2020.12.011 ↗
13. 10.1038/s41418‐022‐00988‐z10.1038/s41418‐022‐00988‐z ↗
14. 10.1016/j.ccell.2018.12.01210.1016/j.ccell.2018.12.012 ↗
15. 10.1038/s41388‐021‐02088‐710.1038/s41388‐021‐02088‐7 ↗
16. 10.1016/S0092‐8674(00)80304‐910.1016/S0092‐8674(00)80304‐9 ↗
17. 10.1016/S0092‐8674(00)80521‐810.1016/S0092‐8674(00)80521‐8 ↗
18. 10.1038/4298110.1038/42981 ↗
19. CREB‐Binding Protein and p300/CBP‐Associated Factor are Transcriptional Coactivators of the p53 Tumor Suppressor Protein
20. 10.1016/S1097‐2765(01)00414‐210.1016/S1097‐2765(01)00414‐2 ↗
21. 10.1074/jbc.M21069620010.1074/jbc.M210696200 ↗
22. Transcriptional Repression by Wild‐Type p53 Utilizes Histone Deacetylases, Mediated by Interaction With mSin3a10.1101/gad.13.19.2490 ↗
23. 10.1101/gad.14.2.14210.1101/gad.14.2.142 ↗
24. 10.1016/S0168‐9525(03)00111‐210.1016/S0168‐9525(03)00111‐2 ↗
25. 10.1016/j.pharmthera.2017.08.00310.1016/j.pharmthera.2017.08.003 ↗
26. FoxN3 is Required for Craniofacial and Eye Development of Xenopus Laevis10.1002/dvdy.21007 ↗
27. 10.1128/MCB.23.13.4522‐4531.200310.1128/MCB.23.13.4522‐4531.2003 ↗
28. 10.1158/0008‐5472.CAN‐06‐006110.1158/0008‐5472.CAN‐06‐0061 ↗
29. 10.1016/j.gene.2005.06.01410.1016/j.gene.2005.06.014 ↗
30. 10.18632/oncotarget.978910.18632/oncotarget.9789 ↗
31. 10.1038/ng153210.1038/ng1532 ↗
32. 10.1002/ijc.2066310.1002/ijc.20663 ↗
33. 10.1111/ejh.1231810.1111/ejh.12318 ↗
34. Gene Expression Profile Analysis in Laryngeal Cancer by High‐Density Oligonucleotide Microarrays
35. 10.1002/gcc.2220410.1002/gcc.22204 ↗
36. Transcriptomic Profiling of Forkhead Box Transcription Factors in Adult Glioblastoma Multiforme
37. Development of a Highly Specialized cDNA Array for the Study and Diagnosis of Epithelial Ovarian Cancer
38. 10.1093/nar/gkad05710.1093/nar/gkad057 ↗
39. 10.1158/0008‐5472.CAN‐21‐076310.1158/0008‐5472.CAN‐21‐0763 ↗
40. 10.1038/s41467‐025‐56922‐710.1038/s41467‐025‐56922‐7 ↗
41. 10.1038/s41588‐024‐02039‐410.1038/s41588‐024‐02039‐4 ↗
42. 10.1126/scitranslmed.abn915510.1126/scitranslmed.abn9155 ↗
43. 10.1038/s41568‐025‐00826‐710.1038/s41568‐025‐00826‐7 ↗
44. 10.1038/s41586‐023‐06253‐810.1038/s41586‐023‐06253‐8 ↗
45. Bone Marrow Mesenchymal Stem Cells Suppress IL‐9 in Adjuvant‐Induced Arthritis10.1080/08916934.2018.1428956 ↗
46. 10.1093/nar/gkad05710.1093/nar/gkad057 ↗
47. 10.1172/JCI9423310.1172/JCI94233 ↗
48. 10.1016/j.mce.2020.11092510.1016/j.mce.2020.110925 ↗
49. 10.1038/s41467‐022‐34239‐z10.1038/s41467‐022‐34239‐z ↗
50. 10.1016/j.jhep.2014.12.03310.1016/j.jhep.2014.12.033 ↗
51. 10.1093/cvr/cvq26510.1093/cvr/cvq265 ↗
52. 10.1016/j.heliyon.2023.e1384310.1016/j.heliyon.2023.e13843 ↗
53. 10.1016/j.yjmcc.2018.11.00110.1016/j.yjmcc.2018.11.001 ↗
54. 10.1093/nar/gkag17110.1093/nar/gkag171 ↗
55. 10.1016/j.ymthe.2023.01.02510.1016/j.ymthe.2023.01.025 ↗
56. 10.1016/j.atherosclerosis.2018.12.01210.1016/j.atherosclerosis.2018.12.012 ↗